Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer

D. D. von Hoff, D. S. Alberts, D. E. Mattox, S. Coulthard, B. Dana, M. Manning, J. W. Myers, C. B. Griffin

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Twenty-six patients with advanced head and neck cancer, 22 of whom had failed prior surgery and/or radiotherapy, were treated with a combination regimen of cis-diamminedichloroplatinum II, bleomycin, and methotrexate. There were no complete responses. Nine patients achieved a partial response (35%). Three of the four (75%) patients without prior therapy achieved a partial response while only 6 of the 22 patients (27%) with prior surgery and/or radiation therapy obtained a partial response. The median response duration was 3 months. Patients with a partial response did not live significantly longer than those who did not respond. Toxic reactions were frequent: there were three episodes of sepsis secondary to leukopenia and two cases of bleomycin pulmonary toxicity. Mucositis was noted in 40% and nausea and vomiting in 60% of patients. We conclude that this triple-drug regimen has little value in the treatment of patients with advanced squamous cell carcinoma of the head and neck who have failed prior surgery and radiotherapy.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalCancer Clinical Trials
Volume4
Issue number2
StatePublished - Dec 1 1981
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer'. Together they form a unique fingerprint.

  • Cite this

    von Hoff, D. D., Alberts, D. S., Mattox, D. E., Coulthard, S., Dana, B., Manning, M., Myers, J. W., & Griffin, C. B. (1981). Combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with advanced head and neck cancer. Cancer Clinical Trials, 4(2), 215-218.